SAN FRANCISCO Attorneys from Latham & Watkins in Silicon Valley are helping Redwood City-based OncoMed Pharmaceuticals Inc. go public in what could be one of the largest IPOs by a Bay Area life sciences company in months.
Partners Alan Mendelson and Mark Roeder, co-chairs of Latham’s life sciences group, are advising the cancer drug developer, which is seeking to raise $115 million in its IPO, according to registration papers filed on Friday.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
